The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower

Thu, 22nd Dec 2022 12:10

(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant.

The FTSE 100 index was up 34.11 points, 0.5%, at 7,531.43. The FTSE 250 was up 62.80 points, 0.3%, at 18,926.45 , and the AIM All-Share was down just 0.2 of a point, at 830.22.

The Cboe UK 100 was up 0.4% at 752.75, the Cboe UK 250 was up 0.4% at 16,376.71, and the Cboe Small Companies was up 0.1% at 12,933.78.

"The markets seem to be heading into Christmas on a slightly more hopeful note amid signs the US consumer is proving more resilient than feared," said AJ Bell investment director Russ Mould.

This positivity did not extend to European equities, which had fallen into the red by early afternoon Thursday. The CAC 40 in Paris was marginally lower, while the DAX 40 in Frankfurt was down 0.2%.

Consumer confidence in the US economy improved in December, bouncing more than expected as inflation expectations eased and gasoline prices cooled, survey data showed on Wednesday.

The closely watched consumer confidence index rose more than analysts predicted to 108.3 points this month, markedly higher than the revised 101.4 figure in November, said think tank the Conference Board.

There are more US economic indicators to come on Thursday, with US weekly unemployment insurance claims, as well as a gross domestic product print, and personal consumption expenditures.

Annualised US GDP growth is expected to be confirmed at 2.9% in the third quarter.

The dollar was mixed ahead of the data, while stocks in New York were called lower.

Sterling was quoted at USD1.2062 early Thursday, lower than USD1.2093 at the London equities close on Wednesday. The euro traded at USD1.0629, higher than USD1.0612. Against the yen, the dollar was quoted at JPY132.18, firm versus JPY132.08.

The Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite all were called down 0.3%.

Earlier on Thursday, a new UK GDP print showed a sharper decline in the third quarter than previously forecast.

The UK economy is now estimated to have contracted by 0.3% between July to September. This was downwardly revised from a previous estimate of a 0.2% decline. It mainly reflects revisions to production and construction output estimates, ONS said.

The estimates were adjusted due to the additional bank holiday in September for the state funeral of Queen Elizabeth II, which saw businesses close or reduce their operations.

Meanwhile, annual real UK GDP was revised upwards to 7.6% growth in 2021 from a previous estimate of 7.5%. Despite this, downward revisions in 2022 meant that real GDP is now estimated to be 0.8% below its pre-pandemic size.

This compares with a previous estimate of being just 0.4% below. The estimate shows the UK is the only G7 country to continue to fall short of its pre-pandemic performance.

"There is clearly a caveat in that the UK did shutter shops and close offices and factories to allow people to take time off to pay their respects to the late Queen. But all in all, it's hard to find the silver lining in these gathering storm clouds," said AJ Bell's Danni Hewson.

Gold was quoted at USD1,814.65 an ounce at midday on Thursday, edging down from USD1,815.20 on Wednesday. Brent oil fetched USD83.69 a barrel, higher than USD81.68.

In London, FTSE 100 heavyweights BP and Shell were up 1.7% and 1.0% respectively, tracking the oil price higher.

Amid a more risk-on mood, defensive stocks such as United Utilities and British American Tobacco were succumbing to selling pressure, losing 2.1% and 1.2% respectively.

In the FTSE 250, DiscoverIE was up 1.0%, having returned some of its early morning gain.

The specialised electronic components firm has acquired Magnasphere, a US-based company that designs and manufactures magnetic sensors and switches for industrial electronic purposes. It will pay out USD22 million on a debt-free, cash-free basis before expenses, funded from existing debt facilities.

The acquisition will be immediately accretive to underlying earnings and underlying operating margin, discoverIE said.

"This acquisition of Magnasphere continues our strategy of building a differentiated, international, growth-focused electronics group with strong operating margin," said discoverIE Chief Executive Nick Jefferies.

On AIM, Tekmar surged up 50%.

The offshore energy markets services and technology provider won a new contract to supply cable protection systems to phase three of the UK's Dogger Bank C wind farm. The award comes from DEME Offshore.

The 3.6 gigawatt wind farm is located off the north east coast of England. Tekmar will design, manufacture and supply a further 172 CPS, having already supplied 380 CPS in the A and B project phases at Dogger Bank. It provided no financial details.

Destiny Pharma also added 10%.

The clinical-stage biotechnology company, said the completion of a partnering agreement for its NTCD-M3 phase 3 drug is expected in early 2023.

The company said it had entered exclusive negotiations with a US pharmaceutical company to secure a commercialisation partner for NTCD-M3 - its lead asset for the prevention of clostridioides difficile infection recurrence.

Thursday is the last full day of trading in London before Christmas, before an early finish at 1230 GMT on Friday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.